rewrite this title and make it good for SEOStructure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Structure Therapeutics Inc. stands fifth among them.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases such as obesity and diabetes. Leveraging AI-powered drug discovery, the company designs and optimizes candidates with greater speed and precision, positioning itself as a leading AI-driven biotech innovator.

Structure Therapeutics Inc. (NASDAQ:GPCR)’s lead obesity candidate, aleniglipron (GSBR-1290), is progressing through two Phase 2b studies, ACCESS and ACCESS II, testing doses up to 240 mg to optimize efficacy and competitive positioning. Topline results are expected by year-end 2025, representing a key catalyst for validating its AI-enabled approach in clinical settings. In addition, the company plans to initiate Phase 1 trials for ACCG-2671, an oral amylin receptor agonist, expanding its metabolic disease portfolio with therapies potentially complementary to GLP-1 drugs.

Financially, Structure Therapeutics Inc. (NASDAQ:GPCR) reported a net loss of $61.7 million in Q2 2025, reflecting heavy investment in research and development, with a strong cash position of approximately $786.5 million supporting operations through 2027. Recent presentations at major healthcare investor conferences have highlighted clinical progress, commercialization potential, and the company’s AI-driven innovation strategy.

The firm’s AI-powered platform distinguishes it from traditional biotech firms by focusing on orally available therapies, which could improve patient accessibility and compliance. As the company approaches pivotal Phase 2b readouts for aleniglipron and prepares for ACCG-2671 trials, it demonstrates the potential of AI integration to accelerate drug discovery and strengthen its pipeline in a rapidly growing obesity and metabolic disorder market.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.